Allergan, Adamas settle patent lawsuit with Amneal
- Health, energy stocks hit Wall Street, Microsoft lifts Nasdaq
- Unusual 11 Mid-Day Movers 10/21: (ALKS) (CXRX) (CERC) Higher; (SGY) (MBRX) (STS) Lower
- AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
Traders work at the post where Allergan stock is traded on the floor of the New York Stock Exchange (NYSE) April 6, 2016. REUTERS/Brendan McDermid - RTSDV88
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Reuters) - Allergan Plc said it and Adamas Pharmaceuticals Inc settled a patent infringement lawsuit with Amneal Pharmaceuticals over their Alzheimer's drug.
Allergan said its Forest Labs unit and Adamas had filed a lawsuit against privately owned Amneal, which was seeking regulatory approval for generic versions of Namzaric.
The drug, which has been licensed to Forest by Adamas, had U.S. sales of $12.8 million for the quarter ended June 30.
Under the settlement terms, Forest and Adamas will grant Amneal a license to market generic versions of Namzaric from January 1, 2025.
Other terms of the settlement were not disclosed.
Allergan and Adamas have also sued Amerigen Pharmaceuticals, which seeks to market generic versions of the drug.
(Reporting by Shailesh Kuber; Editing by Anil D'Silva)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exclusive: U.N. chief mulls future in South Korea where he tops presidential polls
- Emerging investors try to navigate new normal of slow trade
- Christie told of NJ 'Bridgegate' closures month before: defendant
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!